Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study

BACKGROUND: The NEJ026 Phase 3 study demonstrated that erlotinib and bevacizumab (BE)-treated NSCLC patients with EGFR mutations had significantly better progression-free survival (PFS) than those treated with erlotinib alone (E). This study included a prospective analysis of the relationship betwee...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:EBioMedicine
Prif Awduron: Fukuhara, Tatsuro, Saito, Haruhiro, Furuya, Naoki, Watanabe, Kana, Sugawara, Shunichi, Iwasawa, Shunichiro, Tsunezuka, Yoshio, Yamaguchi, Ou, Okada, Prof Morihito, Yoshimori, Kozo, Nakachi, Ichiro, Gemma, Prof Akihiko, Azuma, Koichi, Kurimoto, Futoshi, Tsubata, Yukari, Fujita, Yuka, Nagashima, Hiromi, Asai, Gyo, Watanabe, Satoshi, Miyazaki, Masaki, Hagiwara, Prof Koichi, Nukiwa, Prof Toshihiro, Morita, Prof Satoshi, Kobayashi, Prof Kunihiko, Maemondo, Prof Makoto
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Elsevier 2020
Pynciau:
Research paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7334809/
https://ncbi.nlm.nih.gov/pubmed/32629391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2020.102861
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg